Influence of fluvastatin to inflammatory cytokines and urinary albumin in patients with early diabetic nephropathy

Objective To investigate clinical effect of fluvastatin in the treatment of early diabetic nephropathy, to provide a reference for clinical treatment. Methods 90 patients with diabetic nephropathy were selected, the patients were divided into observation group(50 cases) and control group(40 cases). Conventional hypoglycemic therapy used in the control group, and valsartan treatment also used.The observation group received fluvastatin on the basis of treatment of control group.The efficacy, urinary albumin excretion rate, inflammatory markers, serum creatinine and other indicators and adverse reactions were compared. Results The effective rate of the observation group was 90.00%, which was significantly higher than 75.00% of the control group, the difference was statistically significant (χ2=4.325, P<0.05). After treatment, the BUN, UAER, TC, TG, LDL of the observation group were (6.54±1.24)mmol/L, (40.43±4.21)μg/min, (3.81±0.47)mmol/L, (2.51±0.34)mmol/L, (2.41±0.64)mmol/L, the improvement was better than the control group, the differences were statistically significant (t=5.547, 5.225, 5.457, 4.957, 5.339, all P<0.05). After treatment, the CRP, IL-6, IL-18, TNF-α in the observation group and control group were significantly improved compared with before treatment, the differences were statistically significant (P<0.05). After treatment, the CRP, IL-6, IL-18, TNF-α levels of the observation group were (4.14±0.87)mg/L, (88.17±8.54)pg/mL, (139.64±9.48)ng/L, (40.17±5.22)ng/L, the improvement was better than the control group, the differences were statistically significant (t=6.914, 6.357, 5.847, 7.054, all P<0.05). Conclusion Fluvastatin in the treatment of early diabetic nephropathy has good effect, which will help to improve inflammatory cytokines and proteinuria and protect renal function, it is worthy of clinical application. Key words: Diabetic nephropathy; Cytokines; Proteinuria; Fluvastatin